CA3172692C - 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof - Google Patents
1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof Download PDFInfo
- Publication number
- CA3172692C CA3172692C CA3172692A CA3172692A CA3172692C CA 3172692 C CA3172692 C CA 3172692C CA 3172692 A CA3172692 A CA 3172692A CA 3172692 A CA3172692 A CA 3172692A CA 3172692 C CA3172692 C CA 3172692C
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound represented
- linear
- halogen
- branched alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010330893 | 2020-04-26 | ||
| CN202010330893.1 | 2020-04-26 | ||
| CN202110288141 | 2021-03-17 | ||
| CN202110288141.8 | 2021-03-17 | ||
| PCT/CN2021/089660 WO2021218863A1 (zh) | 2020-04-26 | 2021-04-25 | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3172692A1 CA3172692A1 (en) | 2021-11-04 |
| CA3172692C true CA3172692C (en) | 2024-05-14 |
Family
ID=78374068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172692A Active CA3172692C (en) | 2020-04-26 | 2021-04-25 | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12559471B2 (https=) |
| EP (1) | EP4144725B1 (https=) |
| JP (1) | JP7693709B2 (https=) |
| KR (1) | KR102832951B1 (https=) |
| CN (1) | CN115667236B (https=) |
| AU (1) | AU2021262281B2 (https=) |
| BR (1) | BR112022021228A2 (https=) |
| CA (1) | CA3172692C (https=) |
| WO (1) | WO2021218863A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115605202B (zh) | 2020-03-26 | 2025-10-28 | 盐野义制药株式会社 | 具有血清素受体结合活性的芳香族杂环衍生物 |
| CN121039114A (zh) | 2023-04-21 | 2025-11-28 | 江苏恩华药业股份有限公司 | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物枸橼酸盐的晶型、制备方法及其应用 |
| WO2025044768A1 (zh) * | 2023-08-29 | 2025-03-06 | 江苏恩华药业股份有限公司 | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物的制备方法和其中间体及其制备方法 |
| CN120329280A (zh) * | 2024-01-17 | 2025-07-18 | 江苏恩华药业股份有限公司 | 取代的1,2,4-四氢-3h-苯并二氮䓬-3-酮衍生物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60161986A (ja) * | 1983-12-24 | 1985-08-23 | Nippon Soda Co Ltd | イミダゾ（１，５−ａ）ピリジン−３−オン誘導体及びその製造方法 |
| ES2197160T3 (es) * | 1992-12-21 | 2004-01-01 | Smithkline Beecham Corp | Antagonistas fibronogeno bicicliclos. |
| EP0960104B1 (en) * | 1996-04-17 | 2004-06-16 | Bristol-Myers Squibb Pharma Company | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
| GT199800109A (es) * | 1997-08-06 | 2000-01-13 | Derivados de n-sulfonilglicinalquiniloxifenetilamida microbicidas. | |
| JP2003503476A (ja) * | 1999-07-06 | 2003-01-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | 環化アミド誘導体 |
| SI1720836T1 (sl) * | 2004-02-25 | 2014-06-30 | Eli Lilly And Company | 6-substituirani 2,3,4,5-tetrahidro-1h-benzo (d)azepini kot agonisti 5-ht2c receptorja |
| KR101594898B1 (ko) | 2005-07-15 | 2016-02-18 | 알바니 몰레큘라 리써치, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| US7473778B2 (en) * | 2005-12-24 | 2009-01-06 | Boehringer Ingelheim International Gmbh | 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one |
| US20100222326A1 (en) | 2007-04-27 | 2010-09-02 | Ucb Pharma, S.A. | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders |
| JP5502733B2 (ja) * | 2007-07-26 | 2014-05-28 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ２ａ及びｄ３受容体の二重のモジュレーター |
| US9309200B2 (en) * | 2011-05-12 | 2016-04-12 | AbbVie Deutschland GmbH & Co. KG | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy |
| EP3409658B9 (en) * | 2016-01-29 | 2024-07-17 | ONO Pharmaceutical Co., Ltd. | Tetrahydronaphthalene derivative |
-
2021
- 2021-04-25 JP JP2022563189A patent/JP7693709B2/ja active Active
- 2021-04-25 CA CA3172692A patent/CA3172692C/en active Active
- 2021-04-25 BR BR112022021228A patent/BR112022021228A2/pt unknown
- 2021-04-25 KR KR1020227040086A patent/KR102832951B1/ko active Active
- 2021-04-25 EP EP21796540.9A patent/EP4144725B1/en active Active
- 2021-04-25 WO PCT/CN2021/089660 patent/WO2021218863A1/zh not_active Ceased
- 2021-04-25 CN CN202180029971.7A patent/CN115667236B/zh active Active
- 2021-04-25 AU AU2021262281A patent/AU2021262281B2/en active Active
-
2022
- 2022-10-20 US US18/048,340 patent/US12559471B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7693709B2 (ja) | 2025-06-17 |
| BR112022021228A2 (pt) | 2022-12-06 |
| JP2023522078A (ja) | 2023-05-26 |
| EP4144725B1 (en) | 2025-11-26 |
| KR102832951B1 (ko) | 2025-07-10 |
| AU2021262281A1 (en) | 2022-11-24 |
| US12559471B2 (en) | 2026-02-24 |
| EP4144725A1 (en) | 2023-03-08 |
| WO2021218863A1 (zh) | 2021-11-04 |
| CN115667236A (zh) | 2023-01-31 |
| AU2021262281B2 (en) | 2024-11-28 |
| US20230132621A1 (en) | 2023-05-04 |
| CA3172692A1 (en) | 2021-11-04 |
| CN115667236B (zh) | 2024-04-26 |
| EP4144725C0 (en) | 2025-11-26 |
| KR20230004662A (ko) | 2023-01-06 |
| EP4144725A4 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3172692C (en) | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof | |
| KR102102587B1 (ko) | 피리미디닐 티로신 키나아제 억제제 | |
| JP4488743B2 (ja) | ピペリジン誘導体 | |
| KR20150116907A (ko) | 옥사디아졸 유도체, 및 대사성 글루타메이트 수용체 강화제로서의 그의 용도 - 842 | |
| JP2023522078A5 (https=) | ||
| CN116444484B (zh) | 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物的盐及应用 | |
| JP5465716B2 (ja) | Ｎｋ１受容体アンタゴニストとしての５−［５−［２−（３，５−ビス（トリフルオロメチル）フェニル）−２−メチルプロパノイルメチルアミノ］−４−（４−フルオロ−２−メチルフェニル）］−２−ピリジニル−２−アルキル−プロリンアミド | |
| US7276509B2 (en) | Piperidine derivatives and their use as antagonists of tachykinins | |
| EA012421B1 (ru) | Замещённые производные оксадиазаспиро[5.5]ундеканона и их применение в качестве антагонистов нейрокинина | |
| RU2712968C2 (ru) | Имидазодиазепиновое соединение | |
| EA008189B1 (ru) | Замещенные производные аминоизоксазолина и их применение в качестве антидепрессантов | |
| JP2021104931A (ja) | 含窒素複素環を有するジベンゾアゼピン誘導体 | |
| HK40080583A (en) | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof | |
| HK40080583B (zh) | 1，5-二氢-2，4-苯二氮䓬-3-酮衍生物及其应用 | |
| EA014239B1 (ru) | Производные диаза-спиро-[4,4]нонана в качестве антагонистов нейрокинина (nk1) | |
| WO2019146739A1 (ja) | ドーパミンｄ３受容体拮抗作用を有する縮環化合物 | |
| RU2777915C2 (ru) | Имидазодиазепиновое соединение | |
| HK40089327A (zh) | 含螺环类衍生物、其制备方法和应用 | |
| HK40089327B (zh) | 含螺环类衍生物、其制备方法和应用 | |
| WO2026078446A2 (en) | 5,6-bicyclic 5-ht2ar agonists and uses thereof | |
| JP2023519603A (ja) | 核内受容体に対して活性な化合物 | |
| HK1209284B (zh) | 嘧啶基酪氨酸激酶抑制劑 | |
| TW201307300A (zh) | 趨代謝性麩胺酸受體調節劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220921 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250228 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250228 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250228 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260213 |